Reprogrammed Interchange Llc Sells 7,901 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold 7,901 shares of Vor Biopharma stock at an average price of $37.83, totaling approximately $298,895, which decreased their ownership by 0.49% to 1,597,308 shares.
• Vor Biopharma's stock is currently priced at $37.46, having risen by 2.1%, with a market capitalization of $256.75 million and a 52-week high of $65.80.
• Wall Street analysts have given Vor Biopharma a consensus rating of "Moderate Buy," with target prices ranging from $55.00 to $113.83, indicating positive growth expectations.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $37.83, for a total transaction of $298,894.83. Following the completion of the sale, the insider directly owned 1,597,308 shares of the company's stock, valued at approximately $60,426,161.64. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The shares were sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The shares were sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Stock Up 2.1%

VOR traded up $0.78 during midday trading on Friday, hitting $37.46. The company had a trading volume of 390,504 shares, compared to its average volume of 389,991. Vor Biopharma Inc. has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a market capitalization of $256.75 million, a price-to-earnings ratio of -22.70 and a beta of 2.05. The stock's 50 day moving average price is $38.88 and its 200 day moving average price is $24.15.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Stifel Nicolaus raised shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price for the company in a research report on Wednesday, September 24th. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $113.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Vor Biopharma in the second quarter valued at about $66,000. Money Concepts Capital Corp boosted its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma in the first quarter valued at about $100,000. Finally, Two Sigma Investments LP boosted its stake in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares during the last quarter. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.